Original from: genomeweb
One Biosciences, a French startup pursuing single-cell tumor RNA sequencing, said on Thursday that it has raised �15 million ($17.4 million) Series A financing.
Redmile Group and Blast led the round, joined by Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.
In a statement, One Biosciences said the proceeds will accelerate clinical development of its platform and help it build partnerships with pharmaceutical and biotech companies.
"This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development," CEO Hedi Ben Brahim said in a statement.
Founded in 2020, the Paris-based firm has now raised more than �20 million. It is hoping that its single-cell transcriptomics approach will drive better clinical decision-making, therapy development, and help optimize clinical trials.
"This investment, coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets, will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical-grade specimens," One Biosciences Cofounder and Curie Institute researcher Céline Vallot said in a statement.
Source: French Single-Cell Startup One Biosciences Raises �15M in Series A Financing
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.